Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyFlorida Blue Specialty Drug Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    New to Market and Specialty Prescription Drug Coverage List and Prior Authorization Requirements

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs coverage, prior authorization, limited distribution, and quantity limits for newly marketed and specialty prescription medications for Florida Blue members and providers. Affects pharmacy benefit management, prescribing providers, and in-network specialty pharmacies.

    Policy Summary
    PayerFlorida Blue
    PolicyNew to Market and Specialty Prescription Drug Coverage List and Prior Authorization Requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization for drugs marked PA and consult the New to Market list, member contract, and Prior Authorization Program Information and Forms for coverage determinations.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multiplelisted drugs
    manyPA required
    manyLDD
    CVSIpreferred pharmacy (hemophilia)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10/1/21
    list effective date

    Coverage criteria and access rules

    Coverage criteria and operational rules

    Coverage and access are determined after Pharmacy Therapeutics Committee review and per member contract; many drugs require prior authorization and/or are limited distribution.

    The Pharmacy Therapeutics Committee must review newly marketed prescription medications before they may be covered; the Committee determines whether the medication will be covered and which tier applies based on safety, efficacy, and availability of other products in the class.
    Refer to the member contract benefit and the Prior Authorization Program Information and Forms for inclusion in the PA program and determination of coverage.
    Prior Authorization (PA) is required for drugs marked PA on the New to Market / specialty list; PA requirements may vary by plan.
    Limited Distribution Drugs (LDD) are available only from specified dispensing pharmacies; consult the Limited Distribution Drugs resource to identify the appropriate dispensing pharmacy.
    Quantity limits (QL) are specified per drug where noted on the list; consult the list for drug-specific QL values.

    Operational guidance and access rules

    • Member cost share may be higher for self-administered specialty drugs not obtained at in‑network specialty pharmacies such as Accredo or CVSICaremark Specialty Pharmacy.
    • Certain specialty drugs may only be available from a specific specialty pharmacy or location (LDD) and must be obtained from that dispensing pharmacy.
    • CVSICaremark is the preferred in‑network specialty pharmacy for hemophilia products.

    Drug designations and coding details

    Drug designations used on listmixed
    LDDLimited Distribution Drug (dispensing pharmacy can be found on Limited Distribution Drugs list)
    PAPrior Authorization required
    QLQuantity Limit
    Quantity Limit (QL) — specified per drug where QL is noted on the list
    Quantity Limit (QL)Specified per drug on the listed drug table where 'QL' appears next to the drug name
    ScopeApplies to numerous newly marketed and specialty prescription drugs on the New to Market / specialty list (effective 10/1/21)
    How notedDrugs that have a maximum allowable quantity are marked with the designation 'QL' on the list (e.g., Epclusa PA; QL)
    Reference for coverage decisionsConsult member contract benefit and the Prior Authorization Program Information and Forms for final determination

    Prior authorization, reviews, and provider contacts

    Prior Authorization

    Prior Authorization and New-to-Market Review

    Newly marketed prescription medications may not be covered until the Pharmacy Therapeutics Committee reviews the medication to determine coverage and tiering; many drugs on the New to Market list require Prior Authorization (PA). Refer to the member contract benefit and the Prior Authorization Program Information and Forms for PA inclusion and coverage determinations.

    • Coverage and tier are determined based on safety, efficacy, and availability of other products in the class.
    • Drugs marked “PA” on the New to Market list require prior authorization per the PA program.
    Documentation Required

    Provider Contacts for PA and Coverage Questions

    For questions about prior authorization, coverage, or the New to Market list, contact the Provider Contact Center or Member Customer Service as directed on the member ID card.

    Terminology used in this policy

    LDD — Limited Distribution Drug (dispensing pharmacy details)
    DefinitionLDD: Limited Distribution Drug — certain specialty drugs available only from a specific specialty pharmacy or pharmacy location
    Dispensing pharmacy infoThe appropriate dispensing pharmacy can be found on the 'Limited Distribution Drugs' list referenced in the document
    Impact on accessDrugs designated LDD must be obtained from the specified dispensing pharmacy; may affect member cost share and network requirements
    ExamplesMultiple drugs on the list are marked LDD (e.g., Epidiolex LDD, Cinryze LDD, Cutaquig PA; LDD)
    PA — Prior Authorization
    DefinitionPA: Prior Authorization — an approval process required for certain drugs before coverage is provided
    Policy Summary
    PayerFlorida Blue
    PolicyNew to Market and Specialty Prescription Drug Coverage List and Prior Authorization Requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization for drugs marked PA and consult the New to Market list, member contract, and Prior Authorization Program Information and Forms for coverage determinations.
    SourceLink
    On This Page
    Coverage criteria and access rulesDrug designations and coding detailsPrior authorization, reviews, and provider contactsTerminology used in this policy
  1. Provider Contact Center: 1-800-727-2227 (health care providers and office staff only).
  2. Customer Service: phone number found on the back of the member's insurance card.
  3. How indicatedDrugs that require prior approval are marked 'PA' on the New to Market / specialty drug list (e.g., many entries show 'PA' next to the drug name)
    Where to confirmRefer to the member contract benefit and the Prior Authorization Program Information and Forms for inclusion in the PA program and final coverage determination
    Operational notePA requirements may vary by plan; some specialty drugs may not be covered by certain plans
    QL — Quantity Limit
    DefinitionQL: Quantity Limit — denotes a maximum allowable quantity for a medication as shown on the drug list
    How shownMarked as 'QL' adjacent to drug names in the New to Market / specialty list (e.g., Epclusa PA; QL; Afinitor PA, QL)
    ScopeApplies to multiple listed drugs; specific limit amounts are specified per drug in the list
    Related guidanceConsult the drug table and member contract for exact quantity limits and coverage implications